arrow
J

Jérôme Hadjadj

INSERM
H指数:34
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characteristics of patients with isolated anti-Ku antibodies

孤立性抗Ku抗体患者的特征

2026-10-230
PRE
Erdheim-Chester disease associated with myeloid neoplasm: Clinical features, molecular landscape, and treatment outcomes

Erdheim-Chester disease与髓系肿瘤相关的临床特征、分子景观及治疗结局

2026-04-080
OAAI
Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors

IDH突变髓系肿瘤中的炎症性疾病:特征及对IDH抑制剂的应答

2025-11-250
OAAI
Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome – an international multicenter study

阿那白滞素(anakinra)和卡那单抗(canakinumab)在VEXAS综合征患者中的比较疗效与安全性——一项国际多中心研究

2025-09-220
OAAI
Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

阿扎胞苷治疗VEXAS综合征的疗效与安全性:FRENVEX小组的一项大规模回顾性研究

Blood
IF23.1
2025-05-190
PRE
Comparative benchmarking of the DeepSeek large language model on medical tasks and clinical reasoning

DeepSeek大语言模型在医学任务和临床推理中的比较基准测试

2025-04-231
PRE
Relevance of anti-platelet factor 4/heparin antibodies and platelet activation in systemic inflammatory diseases and thrombosis disorders: insight from the COVID-19 pandemic
2025-02-010
OAAI
Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study

SOCS1缺乏个体的临床表现、疾病外显率及治疗:一项基于注册和人群的研究

2025-02-010
OAAI
New Therapeutic Perspectives in Type B Insulin Resistance Syndrome: Efficacy of a Multitarget Therapy With Obinutuzumab and Mycophenolate Mofetil in Two Patients With Insulin Receptor Autoantibodies and Systemic Lupus Erythematosus

B型胰岛素抵抗综合征的新治疗视角:奥滨尤妥珠单抗与霉酚酸酯联合多靶点疗法在2例胰岛素受体自身抗体合并系统性红斑狼疮患者中的疗效

2025-01-290
PRE
A Clinicopathological Description of Kidney Features in VEXAS Syndrome
2025-01-010
OAAI
Angioedema Due to Acquired C1-Inhibitor Deficiency Without Hematological Condition: A Multicenter French Cohort Study of 34 Patients
2025-01-010
PRE
Angioedema due to Acquired C1-Inhibitor Deficiency Associated With Monoclonal Gammopathies of Undetermined Significance Characteristics of a French National Cohort

法国国家队列的特征与未确定的意义的单克隆丙种球蛋白病相关的获得性C1-Inhibitor缺乏症引起的血管性水肿

2024-12-010
OAAI
Clinical Efficacy of Erythroid Stimulating Agent (ESA) and Luspatercept (LUSPA) in Vexas Syndrome with or without Myelodysplastic Syndrome (MDS) : A Multicenter Retrospective Study By the Frenvex Group

促红细胞生成剂(ESA)和鲁斯帕特cept(LUSPA)在Vexas综合征合并或不合并骨髓增生异常综合征(MDS)中的临床疗效:一项由Frenvex小组进行的回顾性多中心研究

BLOOD
IF23.1
2024-11-050
PRE
JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study
2024-01-0115
PRE